Trial Profile
A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms Morpheus
- Sponsors Meril Life Sciences
- 19 Feb 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 19 Feb 2020 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 11 Apr 2018 Planned End Date changed from 1 May 2020 to 1 Dec 2020.